Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Palvella Therapeutics Inc (PVLA)

Palvella Therapeutics Inc (PVLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations

BEYONDmLM.com campaign designed to educate, engage, and empower patients, caregivers , and healthcare professionals Campaign developed and launched in close collaboration with leading nonprofit...

PVLA : 142.11 (+3.96%)
Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

WAYNE, Pa., March 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...

PVLA : 142.11 (+3.96%)
Palvella Therapeutics Announces Pricing of Upsized Public Offering

WAYNE, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies...

PVLA : 142.11 (+3.96%)
Stocks Settle Higher as AI Disruption Fears Ease

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +0.77%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.76%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.09%. March E-mini...

AMAT : 345.88 (+2.05%)
HSIC : 76.29 (-2.32%)
DDOG : 123.08 (-4.26%)
EXPD : 141.37 (-2.66%)
TRI : 103.70 (-7.01%)
$IUXX : 24,956.47 (-0.04%)
BWXT : 195.91 (-2.24%)
ASML : 1,383.40 (+1.91%)
ZNM26 : 112-095 (-0.06%)
ESH26 : 6,796.50 (-0.07%)
QCOM : 135.20 (-2.11%)
KEYS : 285.54 (+1.25%)
Palvella Therapeutics Announces Proposed Public Offering

WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies...

PVLA : 142.11 (+3.96%)
Stocks Rally as AI-Fueled Worries Ease

The S&P 500 Index ($SPX ) (SPY ) today is up +0.50%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.75%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.90%. March E-mini S&P futures (ESH26...

INTU : 453.95 (-4.16%)
HSIC : 76.29 (-2.32%)
ADI : 318.81 (-0.28%)
EXPD : 141.37 (-2.66%)
TRI : 103.70 (-7.01%)
TXN : 197.46 (+0.64%)
$IUXX : 24,956.47 (-0.04%)
BWXT : 195.91 (-2.24%)
ZNM26 : 112-095 (-0.06%)
ESH26 : 6,796.50 (-0.07%)
FANG : 178.31 (-2.49%)
QCOM : 135.20 (-2.11%)
Stocks Rebound as Software Stocks Recover

The S&P 500 Index ($SPX ) (SPY ) today is up +0.17%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.64%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.47%. March E-mini S&P futures (ESH26...

INTU : 453.95 (-4.16%)
HSIC : 76.29 (-2.32%)
HIMS : 23.47 (+5.91%)
DDOG : 123.08 (-4.26%)
EXPD : 141.37 (-2.66%)
PAY : 26.02 (+0.93%)
$IUXX : 24,956.47 (-0.04%)
BWXT : 195.91 (-2.24%)
ZNM26 : 112-095 (-0.06%)
ESH26 : 6,796.50 (-0.07%)
QCOM : 135.20 (-2.11%)
KEYS : 285.54 (+1.25%)
Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations

Primary endpoint met with statistically significant improvement (mean change of +2.13; p

PVLA : 142.11 (+3.96%)
Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations 

WAYNE, Pa., Feb. 23, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA)  Palvella Therapeutics , Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing...

PVLA : 142.11 (+3.96%)
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in...

Publication includes a systematic review of 24 studies describing off-label cutaneous application of statins in porokeratosis   Preliminary case reports suggesting clinical benefit underscore...

PVLA : 142.11 (+3.96%)

Barchart Exclusives

BioNTech Stock Plunges as Founders Leave. Should You Buy the Dip in BNTX Here?
BioNTech shares are crashing as the company posted a disappointing Q4 release and announced cofounders departure by the end of 2026. Here’s why BNTX stock is still worth buying today. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar